ホーム › 非ホジキンリンパ腫 › オハイオ › Columbus
Columbus、OHにおける非ホジキンリンパ腫の臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、非ホジキンリンパ腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
被験者募集中第3相
- Study Site 104, Columbus
Epco, Zanu, Ritux for R/R FL or MZL
被験者募集中第2相
- The Ohio State University Wexner Medical Center, Columbus
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- The Ohio State University (OSU), Columbus
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
被験者募集中第2相
- Research Site, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- The Ohio State University Wexner Medical Center James Cancer, Columbus
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- The Ohio state University, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
被験者募集中第1相
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- The Ohio State University, Columbus
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
被験者募集中第1相
- The Ohio State University, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Memorial Hospital, Marysville · 27マイル先
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
被験者募集中第1相
- The Ohio State University - The James Cancer Hospital, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
被験者募集中第1相
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
他の都市における非ホジキンリンパ腫の試験
- New York City, NY31件の研究
- Houston, TX31件の研究
- Boston, MA26件の研究
- Nashville, TN21件の研究
- Philadelphia, PA20件の研究
- Baldwin Park, CA19件の研究
- Washington, DC18件の研究
- Chicago, IL18件の研究
- Atlanta, GA18件の研究
- Milwaukee, WI18件の研究
- Dallas, TX17件の研究
- Seattle, WA16件の研究
Columbusにおける他の研究
- 非小細胞肺癌57件の研究
- 乳がん40件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
- 大腸癌24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。